Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?

Alemtuzumab (Campath-1H) has been widely used for T-cell depletion following both conventional and reduced-intensity conditioning allografts. We studied the impact of alemtuzumab used in vivo and in vitro on infections, immune reconstitution, and allograft outcome. The use of alemtuzumab in vivo fol...

書誌詳細
主要な著者:	Chakrabarti, S, Hale, G, Waldmann, H
フォーマット:	Journal article
言語:	English
出版事項:	2004

類似資料

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
著者:: Watson, C, 等
出版事項: (2004)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
著者:: Hale, G, 等
出版事項: (2002)

The evolving role of alemtuzumab (Campath-1H) in renal transplantation
著者:: Phuong-Thu T Pham, 等
出版事項: (2008-12-01)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
著者:: Hale, G, 等
出版事項: (1988)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
著者:: Clatworthy, MR, 等
出版事項: (2009)

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
著者:: Watson, C, 等
出版事項: (2005)

Campath 1 H "in the bag" is an effective method of GvHD prevention in allogeneic stem cell transplantation.
著者:: Potter, M, 等
出版事項: (2000)

Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go
著者:: Lv Meng, 等
出版事項: (2012-03-01)

COMBINED USE OF CAMPATH-1G IN-VIVO AND IN THE BAG IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
著者:: Fibbe, W, 等
出版事項: (1993)

CAMPATH-1 antibodies in stem-cell transplantation.
著者:: Hale, G, 等
出版事項: (2001)

Where do we go from here?
著者:: Rai, Vijesh
出版事項: (2016)

Expert Systems: Where Are We? And Where Do We Go from Here?
著者:: Davis, 等
出版事項: (2004)

Editorial: Where Are We Now and Where Do We Go From Here
著者:: Gabriele Manganaro
出版事項: (2022-01-01)

Availability of Campath-1 antibodies for bone marrow transplantation.
著者:: Hale, G, 等
出版事項: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
著者:: Hale, G, 等
出版事項: (1994)

Alemtuzumab (Campath-1H) para tratamento da leucemia linfóide crônica
著者:: Maria Kadma da Silva Carriço, 等
出版事項: (2003-06-01)

Tractography: where do we go from here?
著者:: Jbabdi, S, 等
出版事項: (2011)

Afterword: Where Do We Go from Here?
著者:: Kimberly Vinall, 等
出版事項: (2017-01-01)

Transplantation tolerance: the big picture. Where do we stand, where should we go?
著者:: Waldmann, H
出版事項: (2017)

Allogeneic stem cell transplantation for lymphoproliferative disease using BEAM-Campath conditioning: An effective regime with low procedure-related toxicity.
著者:: Cull, G, 等
出版事項: (1999)

Commentary: Retinoblastoma management–Where are we and where do we go from here?
著者:: P Mahesh Shanmugam
出版事項: (2020-01-01)

Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
著者:: Lundin, J, 等
出版事項: (2001)

How Did We Get Here and Where are We Going?
著者:: Georgina CHAMBERS
出版事項: (2022-09-01)

Evaluation of non-myeloablative conditioning combining beam with in vivo pre-transplant Campath-IG for allogeneic transplantation in patients with lymphoma.
著者:: Russell, N, 等
出版事項: (1999)

CAMPATH-1H in inflammatory arthritis.
著者:: Watts, R, 等
出版事項: (1993)

COVID-19 - where do we go from here?
著者:: Lee, Pei Hua, 等
出版事項: (2020)

Propriospinal myoclonus: where do we go from here?
著者:: Brown, P
出版事項: (2014)

Oil prices : where do we go from here?/
著者:: 284295 Zanoyan, Vahan
出版事項: (1986)

Math anxiety : where do we go from here? /
著者:: 297422 Hunt, Glen E.

Advanced ceramics : where do we go from here?/
著者:: 348668 Smith, Vincent, 等

Multiple Sclerosis: Where do we go from here?
著者:: Marta Tejera-Alhambra, 等
出版事項: (2016-07-01)

Calibration research: Where do we go from here?
著者:: Linda eBol, 等
出版事項: (2012-07-01)

PITUITARY INCIDENTALOMAS – WHERE DO WE GO FROM HERE?
著者:: Syed Ali Imran
出版事項: (2016-08-01)

Developmental Dyslexia: Where Do We Go from Here?
著者:: Paul E. Engelhardt
出版事項: (2020-03-01)

OMR At Crossroads; Where Do We Go From Here ?
著者:: Mangala Meti
出版事項: (2004-01-01)

Topological photonics: Where do we go from here?
著者:: Segev Mordechai, 等
出版事項: (2020-10-01)

T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival.
著者:: Chakrabarti, S, 等
出版事項: (2003)

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
著者:: Kottaridis, P, 等
出版事項: (2001)

CAMPATH: from concept to clinic.
著者:: Waldmann, H, 等
出版事項: (2005)

Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
著者:: Cull, G, 等
出版事項: (2000)